Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Cleveland Biolabs (CBLI)

Cleveland Biolabs (CBLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,068
  • Shares Outstanding, K 15,479
  • Annual Sales, $ 260 K
  • Annual Income, $ -2,400 K
  • 60-Month Beta 0.70
  • Price/Sales 201.29
  • Price/Cash Flow N/A
  • Price/Book 3.62
Trade CBLI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/16/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +17.41%
on 08/16/21
4.23 -25.06%
on 08/02/21
-1.13 (-26.28%)
since 07/30/21
3-Month
2.70 +17.41%
on 08/16/21
7.10 -55.35%
on 07/06/21
-2.23 (-41.30%)
since 05/28/21
52-Week
1.62 +95.68%
on 09/04/20
10.97 -71.11%
on 02/18/21
+1.29 (+68.62%)
since 08/28/20

Most Recent Stories

More News
Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532

The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome...

CBLI : 3.17 (-7.31%)
Cleveland BioLabs, Inc. Announces Closing of $14 Million Registered Direct Offering of Common Stock

BUFFALO, NY / ACCESSWIRE / February 23, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has closed its previously announced registered direct offering for the issuance and sale of...

CBLI : 3.17 (-7.31%)
Cleveland BioLabs, Inc. Announces $14 Million Registered Direct Offering of Common Stock

BUFFALO, NY / ACCESSWIRE / February 19, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors...

CBLI : 3.17 (-7.31%)
Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.

Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions FORT COLLINS,...

CBLI : 3.17 (-7.31%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of CBLI, NEBC, THCB, and FTOC Mergers

WILMINGTON, Del., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

CBLI : 3.17 (-7.31%)
NEBC : 10.99 (+10.23%)
THCB : 10.00 (-1.96%)
FTOC : 10.76 (+2.38%)
ALERT: Halper Sadeh LLP Investigates CPAH, CBLI, QEP, SNCA; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CPAH : 3.48 (+0.43%)
CBLI : 3.17 (-7.31%)
QEP : 4.08 (-4.45%)
SNCA : 9.9600 (-1.19%)
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, WORK, and UROV

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Lifshitz Law Firm, P.C.: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties...

CBMG : 19.75 (unch)
CBLI : 3.17 (-7.31%)
WORK : 45.20 (+0.09%)
UROV : 16.24 (+0.06%)
MERGER INVESTIGATION ALERT: Halper Sadeh LLP Encourages NK, PRGX, CBLI, and IPHI Shareholders to Contact the Firm

NEW YORK, NY / ACCESSWIRE / January 2, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: NantKwest, Inc. (NASDAQ:NK) concerning potential...

NK : 32.49 (+14.89%)
PRGX : 7.71 (+0.13%)
CBLI : 3.17 (-7.31%)
IPHI : 172.27 (-1.08%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – ALXN, ELY, CLCT, CBLI

NEW YORK, NY / ACCESSWIRE / December 19, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) concerning...

ELY : 24.02 (+3.18%)
ALXN : 182.50 (+1.70%)
CLCT : 91.92 (+0.04%)
CBLI : 3.17 (-7.31%)
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, CBLI, COP, and EIGI

NEW YORK, NY / ACCESSWIRE / December 3, 2020 /Lifshitz Law Firm, P.C.: Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties...

CBMG : 19.75 (unch)
CBLI : 3.17 (-7.31%)
COP : 100.36 (+4.56%)
EIGI : 9.49 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cytocom Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Cytocom Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 3.83
2nd Resistance Point 3.68
1st Resistance Point 3.42
Last Price 3.17
1st Support Level 3.01
2nd Support Level 2.86
3rd Support Level 2.60

See More

52-Week High 10.97
Fibonacci 61.8% 7.40
Fibonacci 50% 6.30
Fibonacci 38.2% 5.19
Last Price 3.17
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar